Literature DB >> 33558723

Androgen receptor agonists as breast cancer therapeutics.

Jennifer L Caswell-Jin1, Christina Curtis2,3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33558723     DOI: 10.1038/s41591-021-01242-8

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


× No keyword cloud information.
  9 in total

1.  The use of testosterone propionate in the treatment of advanced carcinoma of the breast.

Authors:  F E ADAIR; J B HERRMANN
Journal:  Ann Surg       Date:  1946-06       Impact factor: 12.969

2.  Hormones and chemotherapy in breast cancer.

Authors:  R M Kelley
Journal:  Cancer       Date:  1971-12       Impact factor: 6.860

3.  Androgen receptor expression and breast cancer survival in postmenopausal women.

Authors:  Rong Hu; Shaheenah Dawood; Michelle D Holmes; Laura C Collins; Stuart J Schnitt; Kimberley Cole; Jonathan D Marotti; Susan E Hankinson; Graham A Colditz; Rulla M Tamimi
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

Review 4.  Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Authors:  Rachel Schiff; Suleiman Massarweh; Jiang Shou; C Kent Osborne
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

5.  Cooperative Dynamics of AR and ER Activity in Breast Cancer.

Authors:  Nicholas C D'Amato; Michael A Gordon; Beatrice Babbs; Nicole S Spoelstra; Kiel T Carson Butterfield; Kathleen C Torkko; Vernon T Phan; Valerie N Barton; Thomas J Rogers; Carol A Sartorius; Anthony Elias; Jason Gertz; Britta M Jacobsen; Jennifer K Richer
Journal:  Mol Cancer Res       Date:  2016-08-26       Impact factor: 5.852

6.  Androgen receptor as a targeted therapy for breast cancer.

Authors:  Joseph P Garay; Ben H Park
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

Review 7.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Authors:  Francisco E Vera-Badillo; Arnoud J Templeton; Paulo de Gouveia; Ivan Diaz-Padilla; Philippe L Bedard; Mustafa Al-Mubarak; Bostjan Seruga; Ian F Tannock; Alberto Ocana; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2013-11-22       Impact factor: 13.506

8.  A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.

Authors:  Ian Krop; Vandana Abramson; Marco Colleoni; Tiffany Traina; Frankie Holmes; Laura Garcia-Estevez; Lowell Hart; Ahmad Awada; Claudio Zamagni; Patrick G Morris; Lee Schwartzberg; Stephen Chan; Ayca Gucalp; Laura Biganzoli; Joyce Steinberg; Lorenzo Sica; Maureen Trudeau; Denka Markova; Jamal Tarazi; Zhou Zhu; Thomas O'Brien; Catherine M Kelly; Eric Winer; Denise A Yardley
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.